nach oben

Breast Cancer Research

Erschienen in:

01.06.2001 | Commentary

More breast cancer genes?

verfasst von: John L Hopper

Erschienen in: Breast Cancer Research | Ausgabe 3/2001

Einloggen, um Zugang zu erhalten

Abstract

A new gene associated with a high risk of breast cancer, termed BRCAX, may exist on chromosome 13q. Tumours from multicase Nordic breast cancer families, in which mutations in BRCA1 and BRCA2 had been excluded, were analyzed using comparative genomic hybridization in order to identify a region of interest, which was apparently confirmed and refined using linkage analysis on an independent sample. The present commentary discusses this work. It also asks why there should exist genetic variants associated with susceptibility to breast cancer other than mutations in BRCA1 and BRCA2, and what might be their modes of inheritance, allele frequencies and risks. Replication studies will be needed to clarify whether there really is a tumour suppressor gene other than BRCA2 on chromosome 13q.

Kainu T, Juo SH, Desper R, Schaffer AA, Gillanders E, Rozenblum E, Freas-Lutz D, Weaver D, Stephan D, Bailey-Wilson J, Kallion-iemi OP, Tirkkonen M, Syrjakoski K, Kuukasjarvi T, Koivisto P, Karhu R, Holli K, Arason A, Johannesdottir G, Bergthorsson JT, Johannsdottir H, Egilsson V, Barkardottir RB, Johannsson O, Haraldsson K, Sandberg T, Holmberg E, Gronberg H, Olsson H, Borg A, Vehmanen P, Eerola H, Heikkila P, Pyrhonen S, Nevanlinna H: Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA. 2000, 97: 9603-9608. 10.1073/pnas.97.17.9603.CrossRefPubMedPubMedCentral

Cui J, Hopper JL: Why are the majority of hereditary cases of early-onset breast cancer sporadic? A simulation study. Cancer Epidemiol Biomarkers Prev. 2000, 9: 805-812.PubMed

Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA: Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer. 1997, 71: 800-809. 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.3.CO;2-R.CrossRefPubMed

Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-949. 10.1093/jnci/91.11.943.CrossRefPubMed

Becker NG, Hopper JL: The infectiousness of a disease in a community of households. Biometrika. 1983, 70: 29-39.CrossRef

Hopper JL, Carlin JB: Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am J Epidemiol. 1992, 136: 1138-1147.PubMed

Easton DF, Peto J: The contribution of inherited predisposition to cancer incidence. Cancer Surv. 1990, 9: 395-416.PubMed

Aalen OO: Modelling the influence of risk factors on familial aggregation of disease. Biometrics. 1991, 47: 933-946.CrossRefPubMed

Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996, 42: 130-134. 10.1016/S0165-4608(96)00328-7.CrossRef

10.

FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DA: Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nature Genet. 1997, 15: 307-310.CrossRefPubMed

11.

Bishop DT, Hopper JL: AT-tributable risks?. Nature Genet. 1997, 15: 226-CrossRefPubMed

12.

Stankovic T, Kidd AM, Sutcliffe A, McGuire GM, Robinson P, Weber P, Bedenham T, Bradwell AR, Easton DF, Lennox GG, Haites N, Byrd PJ, Taylor AM: ATM mutations and phenotypes in ataxia-telangiectasia families in the British isles: expression of mutant ATM and the risk of leukemia, lymphoma and breast cancer. Am J Hum Genet. 1998, 62: 334-345. 10.1086/301706.CrossRefPubMedPubMedCentral

13.

Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF: A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999, 8: 843-854.PubMed

14.

Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE: A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997, 57: 1063-1065.PubMed

15.

Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE: Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 1998, 58: 585-587.PubMed

16.

Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G: CYP17 promoter polymorphism and breast cancer in Australian women under forty years. J Natl Cancer Inst. 2000, 92: 1674-1681. 10.1093/jnci/92.20.1674.CrossRefPubMed

17.

Bergman-Jungestrom M, Gentile M, Lundin AC, Wingren S: Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer. 1999, 84: 350-353. 10.1002/(SICI)1097-0215(19990820)84:4<350::AID-IJC3>3.0.CO;2-L.CrossRefPubMed

18.

Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, Chang-Claude J, Mannermaa A, Kataja V, Huntsman DG, Pharoah PD, Luben RN, Easton DF, Ponder BA: A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nature Genet. 2000, 26: 362-364. 10.1038/81691.CrossRefPubMed

19.

Antoniou AC, Pharoah PDP, McMullan G, et al: Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol. 2001.

20.

Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, Giles GG, McCredie MR, Hopper JL: After BRCA1 and BRCA2: what next? Multifactorial segregation analyses of three-generational, population-based Australian female breast cancer families. Am J Hum Genet. 2001, 68: 420-431. 10.1086/318187.CrossRefPubMed

21.

Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM: Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?. Am J Hum Genet. 1997, 60: 486-495.PubMedPubMedCentral

22.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed

Titel: More breast cancer genes?
verfasst von: John L Hopper
Publikationsdatum: 01.06.2001
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 3/2001
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr290

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

More breast cancer genes?

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2001

Low frequency of E-cadherinalterations in familial breast cancer

Applications of microarray technology in breast cancer research

Update on endocrine aspects of breast cancer: Report from the 23rd San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 6-9 December 2000

Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy

Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?

The complexities of breast cancer desmoplasia

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie